Humacyte, Inc.
HUMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $753 | $301 | $517 | $7,228 |
| % Growth | 150.2% | -41.8% | -92.8% | – |
| Cost of Goods Sold | $260 | $2,073 | $1,979 | $3,614 |
| Gross Profit | $493 | -$1,772 | -$1,462 | $3,614 |
| % Margin | 65.5% | -588.7% | -282.8% | 50% |
| R&D Expenses | $17,273 | $22,006 | $15,418 | $20,656 |
| G&A Expenses | $0 | $7,809 | $8,136 | $7,432 |
| SG&A Expenses | $7,610 | $7,809 | $8,136 | $11,046 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $3,614 |
| Other Operating Expenses | $0 | -$1,860 | -$1,832 | $0 |
| Operating Expenses | $24,883 | $27,955 | $21,722 | $31,702 |
| Operating Income | -$24,390 | -$29,727 | -$23,184 | -$28,088 |
| % Margin | -3,239% | -9,876.1% | -4,484.3% | -388.6% |
| Other Income/Exp. Net | $6,880 | -$7,931 | $62,323 | $7,148 |
| Pre-Tax Income | -$17,510 | -$37,658 | $39,139 | -$20,940 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,510 | -$37,658 | $39,139 | -$20,940 |
| % Margin | -2,325.4% | -12,511% | 7,570.4% | -289.7% |
| EPS | -0.11 | -0.24 | 0.28 | -0.16 |
| % Growth | 54.2% | -185.7% | 275% | – |
| EPS Diluted | -0.11 | -0.24 | 0.28 | -0.16 |
| Weighted Avg Shares Out | 158,313 | 155,437 | 131,497 | 118,479 |
| Weighted Avg Shares Out Dil | 158,313 | 155,437 | 131,759 | 118,479 |
| Supplemental Information | – | – | – | – |
| Interest Income | $590 | $832 | $662 | $852 |
| Interest Expense | $2,612 | $2,545 | $3,000 | $2,508 |
| Depreciation & Amortization | $1,865 | $1,860 | $1,832 | $1,808 |
| EBITDA | -$13,033 | -$33,253 | $43,971 | -$16,624 |
| % Margin | -1,730.8% | -11,047.5% | 8,505% | -230% |